Cargando…

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile

Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly...

Descripción completa

Detalles Bibliográficos
Autores principales: Leta, Valentina, Dafsari, Haidar S., Sauerbier, Anna, Metta, Vinod, Titova, Nataliya, Timmermann, Lars, Ashkan, Keyoumars, Samuel, Michael, Pekkonen, Eero, Odin, Per, Antonini, Angelo, Martinez-Martin, Pablo, Parry, Miriam, van Wamelen, Daniel J., Ray Chaudhuri, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400869/
https://www.ncbi.nlm.nih.gov/pubmed/34442417
http://dx.doi.org/10.3390/jpm11080773
Descripción
Sumario:Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly focused on patients’ motor profile while non-motor symptoms play a role limited to being regarded as possible exclusion criteria in the decision-making process for the delivery and sustenance of a successful treatment. Differential beneficial effects on specific non-motor symptoms of the currently available device-aided therapies for PD are emerging and these could hold relevant clinical implications. In this viewpoint, we suggest that specific non-motor symptoms could be used as an additional anchor to motor symptoms and not merely as exclusion criteria to deliver bespoke and patient-specific personalised therapy for advanced PD.